Literature DB >> 9636551

Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group.

J F Neylan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9636551     DOI： 10.1016/s0041-1345(98)00274-7

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  9 in total

1.  Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Carl M Kirkpatrick; Katie J Lee; Paul J Taylor; David W Johnson; Scott B Campbell; Diana R Leary; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.

Authors:  W S Oetting; D P Schladt; W Guan; M B Miller; R P Remmel; C Dorr; K Sanghavi; R B Mannon; B Herrera; A J Matas; D R Salomon; P-Y Kwok; B J Keating; A K Israni; P A Jacobson
Journal:  Am J Transplant       Date:  2015-10-20       Impact factor: 8.086

3.  Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.

Authors:  Pamala A Jacobson; William S Oetting; Ann M Brearley; Robert Leduc; Weihau Guan; David Schladt; Arthur J Matas; Vishal Lamba; Bruce A Julian; Rosalyn B Mannon; Ajay Israni
Journal:  Transplantation       Date:  2011-02-15       Impact factor: 4.939

4.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

5.  Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials.

Authors:  G A Knoll; R C Bell
Journal:  BMJ       Date:  1999-04-24

6.  Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.

Authors:  W S Oetting; B Wu; D P Schladt; W Guan; R P Remmel; R B Mannon; A J Matas; A K Israni; P A Jacobson
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

7.  Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.

Authors:  William S Oetting; Baolin Wu; David P Schladt; Weihua Guan; Rory P Remmel; Casey Dorr; Roslyn B Mannon; Arthur J Matas; Ajay K Israni; Pamala A Jacobson
Journal:  Pharmacogenomics       Date:  2018-01-10       Impact factor: 2.533

Review 8.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients.

Authors:  P Dalal; G Shah; D Chhabra; Lorenzo Gallon
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-08-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.